Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomivosertib +/- Avelumab in MSS Colorectal Cancer
NCT03258398Phase 2Completed
- Sponsor
- eFFECTOR Therapeutics
- Start
- Sep 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tomivosertib in colorectal cancer (CRC) (3 arms), sponsored by eFFECTOR Therapeutics. Primary endpoints: Dose Limiting Toxicity at 28 days and Overall Response Rate. Started Sep 2017; status: completed.
02
Drugs
tomivosertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03258398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258398.